Therefore, as Chen and colleagues [14] pointed out, systemic targeting of TNF-α with anti-TNF-α mAbs such as Remicade and Humira is known to create a higher risk of serious infections, and long-term treatment with Remicade may increase lymphoma incidence [14]. This evidence concerns the gene TNF and lymphoma.